Boston Scientific · 3 months ago
AIS R&D Hardware Engineer Intern 2026 (EE)
Boston Scientific is committed to solving important health industry challenges, and they are seeking an R&D Hardware Engineer Intern. This role involves designing and developing implantable medical devices and supporting electrical designs for medical equipment, contributing to innovation in cardiac care.
Health CareMedicalMedical Device
Responsibilities
Contribute to the design and development of implantable medical devices that support diagnosis and treatment of cardiac conditions
Contribute to the development of electrical designs for external medical equipment that communicates with implantable devices
Support testing and validation of electrical designs
Gain exposure to medical device development and cross-functional engineering collaboration
Bring creativity and problem-solving to engineering challenges that address unmet clinical needs and advance cardiac care innovation
Qualification
Required
Current rising junior or rising senior (grad dates between Dec 2026 - May 2028), graduating senior (May 2026 grad) continuing on to grad school, or current grad student. Must have at least one semester of school left post-internship to qualify
Working towards a Bachelors or Masters degree in Electrical Engineering or Biomedical/Computer Engineering with an EE emphasis/experience
Must be able to start internship on May 18th or 26th, 2026 and work for 12 weeks
Must have reliable transportation to/from work
Experience working with electronics, circuit analysis, and circuit design in academic or professional settings
Experience using LabVIEW
Preferred
Medical industry experience
Experience with bench level testing
Ability to communicate effectively with diverse, cross-functional teams
Passion to learn new technologies and find new solutions
Benefits
Corporate housing and relocation are available for those who are eligible.
Company
Boston Scientific
Boston Scientific is a medical technology company that designs and develops medical devices to diagnose and treat a wide range of condition.
Funding
Current Stage
Public CompanyTotal Funding
$10.02B2025-02-21Post Ipo Debt· $1.58B
2024-02-22Post Ipo Debt· $2.17B
2022-03-04Post Ipo Debt· $3.28B
Recent News
BioWorld Financial Watch
2025-12-25
2025-12-12
Company data provided by crunchbase